Hypertensive Disorders in Pregnancy

Hypertension is a common medical complication of pregnancy with consequences for both mother and baby. →

Pre-eclampsia is a progressive multisystem disorder involving new hypertension with proteinuria or other evidence of end-organ dysfunction. →

The passage describes blood pressure thresholds and measurement technique, along with edema and proteinuria findings relevant to pre-eclampsia. →

Multiple reagent strips provide semiquantitative urine protein grades corresponding to the concentrations listed below. →

The passage links abnormal placentation to widespread vascular dysfunction underlying hypertension. →

Normal placentation involves endovascular trophoblast invasion into the walls of spiral arterioles in the uteroplacental bed. →

Normal endovascular trophoblast invasion remodels the spiral arterioles of the uteroplacental bed. →

Normal pregnancy involves changes in spiral arteriolar blood flow and vascular responsiveness that help stabilize blood pressure. →

Vascular endothelial growth factor (VEGF) contributes to the regulation of uteroplacental blood flow in pregnancy. →

Pre-eclampsia is associated with an imbalance between vasodilator prostaglandin and vasoconstrictor thromboxane. →

The discussion of pre-eclampsia describes altered sensitivity to a pressor agent and identifies the sites and substrate of nitric oxide synthesis. →

Vascular mediators, inflammation and placental hypoxia contribute to hypertension and endothelial dysfunction. →

Pre-eclampsia involves vasoconstriction, endothelial dysfunction and disturbances of organ perfusion. →

Pre-eclampsia is associated with an imbalance of angiogenic and antiangiogenic proteins in the placental vascular bed. →

The passage continues the discussion of factors implicated in pre-eclampsia. →

Pre-eclampsia is characterized by endothelial dysfunction and vasospasm. The passage describes contributing mechanisms and probable explanations for edema. →

The proposed mechanism of proteinuria combines glomerular endothelial injury with depressed tubular reabsorption. →

Pathological changes associated with organ dysfunction are well documented, especially in severe pre-eclampsia or eclampsia, although why the syndrome occurs remains unresolved. →

Pre-eclampsia and eclampsia produce pathological changes in the uteroplacental circulation and several maternal organs. →

HELLP syndrome is a complication of pre-eclampsia that may occur even without maternal hypertension. →

The passage describes neurological and cardiopulmonary involvement in hypertensive disorders of pregnancy, including posterior reversible encephalopathy syndrome (PRES). →

Pre-eclampsia combines salt retention and extravascular fluid accumulation with intravascular volume contraction and hematological abnormalities. →

The passage links laboratory abnormalities to disease severity, renal involvement and endothelial damage in pre-eclampsia. →

This passage introduces the severe-feature category of pre-eclampsia or gestational hypertension and begins its blood pressure criterion. →

These abnormalities are listed among the severe features of pre-eclampsia or gestational hypertension. →

The passage describes the mechanism of pulmonary edema and the blood pressure profile listed for pre-eclampsia or gestational hypertension without severe features. →

The passage contrasts the usual onset and progression of the syndrome with its rare acute presentation. →

Pre-eclampsia is principally a syndrome of signs; symptoms usually appear late. →

Severe symptoms may occur singly or together and are usually associated with acute onset of the syndrome. →

Rapid changes in maternal weight may precede visible fluid accumulation in pre-eclampsia. →

Pre-eclampsia may manifest through rapid weight gain, hypertension, edema, and evidence of placental or systemic involvement. →

Severe pre-eclampsia involves several organ systems, as shown by its hematological, renal, hepatic, pulmonary and neurological manifestations. →

The investigations described for pre-eclampsia include assessment of proteinuria and ophthalmoscopic examination for retinal changes. →

Assessment of pre-eclampsia includes maternal blood investigations and fetal wellbeing surveillance because widespread organ dysfunction may progress to end organ damage. →

Early detection and prompt, effective treatment may stabilize the features of pre-eclampsia. →

The passage describes worsening pre-eclamptic features and circumstances in which eclampsia may occur. →

Complications are more likely when pre-eclampsia is untreated. Maternal complications vary across pregnancy, labor, and the puerperium. →

Severe pre-eclampsia is associated with risks in subsequent pregnancies and later cardiovascular, renal, and metabolic health. →

Pre-eclampsia can cause fatal maternal complications and remains associated with substantial perinatal mortality. →

Early recognition of high-risk factors offers an opportunity to reduce complications of pre-eclampsia. →

Screening for pre-eclampsia has explored several types of tests to predict disease onset. →

The passage describes maternal and placental risk factors, proposed disease mechanisms and several approaches to predicting pre-eclampsia. →

The roll over test is a screening test that assesses the diastolic blood pressure response to a change in maternal position. →

The passage describes risk-factor care, antenatal surveillance and exercise as primary preventive measures. →

The passage describes preventive interventions in pregnancy and parameters used to assess pre-eclampsia risk. →

Treatment is described as mostly empirical and symptomatic because the etiology of pre-eclampsia remains obscure. →

Treatment objectives include preventing eclampsia and achieving favorable maternal and neonatal outcomes. →

Women without severe features may receive outpatient care with monitoring in a hospital or day-care center. →

Pre-eclampsia with severe features requires hospitalization until delivery, with blood pressure stabilization and fetal monitoring. →

Hospital admission and rest support continued evaluation and treatment of the patient with pre-eclampsia. →

Dietary guidance accompanies a warning against injudicious diuretic use because of potential harm to the baby. →

The passage describes compelling indications for diuretics and indications for antihypertensive treatment in pre-eclampsia. →

A progress chart is used to evaluate the response to treatment in pre-eclampsia. →

Monitoring follows edema, weight, fluid balance, laboratory findings, and fetal wellbeing; improvement is reflected by favorable clinical and urinary changes. →

Delivery is the definitive treatment for pre-eclampsia, gestational hypertension and eclampsia. The passage also groups maternal risk factors by gestosis score. →

Treatment duration in pre-eclampsia, gestational hypertension, or eclampsia depends on disease severity, pregnancy duration, and maternal and fetal assessment. →

The passage describes continued observation and follow-up for women with gestational hypertension or pre-eclampsia without severe features. →

Women undergoing expectant management for gestational hypertension or pre-eclampsia without severe features are not considered cured. →

Women with gestational hypertension or pre-eclampsia with severe features require admission; management depends on gestation and maternal and fetal stability. →

Continuing pregnancy during expectant management depends on preserving maternal and fetal wellbeing. →

This portion of the pre-eclampsia management scheme lists fetal surveillance methods and antihypertensive options. →

The interpretable branches of the management scheme distinguish stable pregnancies before 34 weeks from cases requiring immediate delivery. →

Management of severe pre-eclampsia includes seizure prophylaxis, prevention of maternal cardiovascular complications and induction appropriate to cervical ripeness. →

The passage describes anesthetic considerations and care during labor and after delivery in women with pre-eclampsia. →

Gestational hypertension describes newly elevated blood pressure without proteinuria in a previously normotensive woman during the specified pregnancy or immediate postpartum period. →

Acute fulminant pre-eclampsia, also called the pre-eclamptic state, involves acute onset or rapid deterioration with a constant threat of serious complications. →

The constant threat of eclampsia makes maternal interest central to decisions about delivery. →

The interpretable portions of the monitoring table describe maternal observations and fetal surveillance during care for severe pre-eclampsia. →

The target passage classifies pre-eclampsia by gestational age and lists maternal and fetal abnormalities. The list's specific management heading is not supplied. →

Eclampsia can begin abruptly, although preceding severe pre-eclampsia is common. →

The passage defines eclampsia by the neurological complications accompanying pre-eclampsia. →

Eclampsia is a severe form of pre-eclampsia and may also occur when pre-eclampsia is superimposed on essential hypertension or chronic nephritis. →

The passage continues the proposed causes of cerebral irritation and classifies eclamptic fits by their onset relative to labor and delivery. →

Eclampsia may be classified by the timing of convulsions. Cerebral abnormalities and atypical neurological features guide further assessment. →

Eclamptic patients usually have premonitory manifestations of acute fulminating preeclampsia. Eclamptic fits are epileptiform and have four stages. →

Eclampsia must be distinguished from other causes of convulsions or coma during pregnancy or soon afterward. →

Once convulsions occur, maternal prognosis becomes uncertain. Prognosis includes immediate maternal risks, recovery and subsequent pregnancy outcomes, and fetal survival. →

The passage identifies measures during preeclampsia that help prevent eclampsia and lists several associated complications. →

The readable intravenous regimen describes loading and maintenance treatment for severe pre-eclampsia and eclampsia. →

Eclampsia can present atypically, making prediction difficult, and is not always preventable. →

The immediate first-aid priority concerns patients with eclampsia at home or in peripheral health centers. →

An eclamptic patient requires transfer to a tertiary care center with neonatal and obstetric intensive care management. →

Supportive care in eclampsia focuses on protecting the mother from injury and maintaining breathing. →

Medical and nursing management combines seizure and blood pressure control with airway care, close observation and preparation for obstetric management. →

Once an eclamptic patient is stabilized, clinical examination and urinary assessment are undertaken. →

Monitoring includes maternal vital signs and urine output, with assessment of labor and fetal heart rate if the patient remains undelivered. →

Fluid administration requires care because hypovolemia can coexist with tissue fluid overload in pre-eclampsia–eclampsia. →

Anticonvulsant treatment addresses both ongoing fits and the risk of further convulsions. →

Magnesium sulfate is the drug of choice in the anticonvulsant management of eclampsia. Its effects, intravenous preparation and conditions for repeat dosing are described. →

During magnesium sulfate treatment for eclampsia, serum concentration, renal function and signs of toxicity guide selected monitoring. →

The passage describes serum magnesium concentrations during seizure prophylaxis and control, along with a dose consideration and treatment of cardiac toxicity. →

The passage continues magnesium sulfate treatment for eclampsia and describes recurrent seizure treatment, toxicity findings, and toxicity management. →

The passage describes benefits of magnesium sulfate, treatment of persistent hypertension and pulmonary edema, and measures during a fit. →

The passage describes treatment for status eclampticus, escalation when treatment fails, and indications for intubation. →

The passage describes intensive care, infection prevention and treatment of pulmonary edema and heart failure in eclampsia. →

Management includes treatment of renal and temperature disturbances, intensive multidisciplinary care, and delivery planning after maternal stabilization. →

Obstetric management considers seizure control, fetal status, gestational age and obstetric indications for cesarean delivery. →

The available flowchart fragment identifies the initial conditions for continuing medical management in eclampsia. →

The interpretable portion of this management flowchart identifies assessment of the mother and fetus. →

The passage covers postpartum anticonvulsant treatment, neurologic evaluation, follow-up and presentations that do not meet standard pre-eclampsia criteria. →

Chronic hypertensive disease is distinguished by hypertension predating pregnancy or appearing before 20 weeks and persisting beyond 12 weeks after delivery. →

Essential hypertension is a common hypertensive state in pregnancy apart from pregnancy-specific hypertensive disorders. →

Essential hypertension is distinguished from pregnancy-associated hypertension by its earlier onset and persistence after delivery. Pregnancy may alter its course and increase complications. →

The passage relates fetal and perinatal risks to the severity of chronic hypertension and outlines blood pressure treatment and obstetric management. →

Chronic renal disease is reported in 0.2% of pregnancies. Urine microscopy and serum biochemical findings can suggest the diagnosis, while prognosis varies with renal impairment. →

Renal disease affects pregnancy outcomes, and pregnancy can worsen renal disease. The severity of renal impairment and superimposed pre-eclampsia influence prognosis. →

Pregnancy complicated by renal disease requires close fetal surveillance and individualized delivery planning. →

Pregnancy in a renal transplant recipient requires prepregnancy counseling and additional surveillance because maternal complications and graft-related concerns influence care. →

The target passage completes postpartum management after renal transplantation and then reviews the defining features and pathological basis of pre-eclampsia. →

This passage links endothelial dysfunction and vasospasm to clinical manifestations and summarizes classification and management. →

The passage summarizes prevention, delivery, blood pressure control, and magnesium sulfate use, with additional distinctions concerning gestational hypertension and HELLP syndrome. →

Gestational hypertension (GH) can evolve into pre-eclampsia (PE). Disease progression may be rapid, so management depends on severe features and gestational age. →